A healthcare venture capital investment firm based in Boston, Massachusetts recently raised a healthcare IT and services fund of over $250 million. The firm generally makes investments in early stage companies targeting healthcare technology and services. The investment size will vary, depending on the opportunity. The firm typically invests in companies based in the United States though is open to companies based on a global level.

In the healthcare technology sector, the firm is actively seeking new investments in healthcare software and tech-enabled services sectors with a specific focus on payment reform, patients as consmers, healthcare analytics, healthcare infrastructure, and novel service delivery models. The firm has a specific interest in transformational technologies and services that enable value-based healthcare. The firm currently is not focused on therapeutics or traditional medical device investment opportunities, though may consider medical devices with a software/data component, such as sensors, that have either already obtained FDA clearance or are not subject to FDA regulation. The firm is indication agnostic and invests in pre-revenue to growth stage products.

The firm seeks to invest in privately held companies with a strong and experience management team. The group prefers to invest in companies with cutting-edge technologies and large market potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A midwest-based VC firm invests in several sectors, including health and life sciences.  Within healthcare, the firm invests primarily in digital heath and digital therapeutics technologies, although they will consider medical device and diagnostics companies. In addition, the firm is also now interested in investing in cell and gene therapies and manufacturing technologies as well. The firm is highly flexible regarding investment size, and will allocate from $1-50M depending on the opportunity and stage of development, with a smaller range of $2-5M for cell and gene therapy technologies. The firm frequently invests in businesses with a significant presence in the Midwest, but will consider strong opportunities elsewhere in the US, or global companies expanding to the US.

For digital health and digital therapeutics companies, the firm will invest in all stages, from pre-revenue to companies with revenue in the tens of millions, and will tailor their investment size accordingly. The firm is fairly agnostic to the type of technology, but is less interested in provider-focused tech. While the firm will consider tech-enabled medical devices and diagnostics companies, this is a secondary interest. The firm is also now investing in pre-clinical cell and gene therapy technologies, as well as companies developing manufacturing techniques for these therapies.

The firm generally prefers to lead investments, but is more likely to co-invest in companies in the cell and gene therapy space. The firm is flexible about board representation, but is more likely to take a board seat in digital-based technology companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly launched investment fund seeks to provide seed financing in promising therapeutics to help establish proof of concept for new clinical compounds and to identify novel clinical uses for existing therapeutics. The firm’s founder has robust experience with investing in and operating biotechnology and healthcare companies, and seeks to leverage this expertise to help foster innovation. The firm’s initial size of investment will be in the range of $250K to $1M. The firm has been in active discussions with academia and corporate-funded researchers to identify promising early-stage therapeutic candidates. In addition to traditional investment approaches, the firm is interested in new company creation based on promising drug candidates. For traditional investment, the firm will prioritize companies that are based in the USA, but will seek global assets for potential in-licensing and company creation around this IP. The firm expects to invest and work with 5-10 companies across the fund.

The firm is primarily interested in small molecule therapeutics, as the cost of characterizing new biologics and cell therapies is outside of its investment scale. The firm is seeking very early-stage, pre-IND assets, and will assist with successful IND filing and completion of required studies. The firm primarily seeks therapeutics for rare diseases that qualify for orphan drug designation, but apart from that the firm is indication agnostic.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An innovation arm of a global company nurtures innovative ideas developed internally and also forms external partnerships with startups in fields that are strategically relevant for the company’s business objectives. These partnerships may include co-development, in-kind services and/or early stage financial investments. The firm partners with startups based anywhere in the world.

The firm is interested in life science startups developing products that are strategically relevant to the parent company. Sectors of interest include devices that make use of semiconductors or advanced engineering, diagnostic sensors, point of care diagnostics and health monitoring. Digital health opportunities may also be of interest.  The firm may also consider investing in combination products. The firm is open to working with companies at a very early stage of development.

The firm is only interested in companies that have a long-term strategic alignment with the firm. Partnerships generally involve providing access to the firm’s expertise and development support, in addition to potentially making a financial investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An innovation arm of a large health system is responsible for sourcing external facing innovation outside of the health system’s network, and seeks various strategic partnering opportunities with early-stage companies.  With a meaningful appetite for risk, the firm seeks to partner with companies through a combination of in-kind and other co-development resources, with an intention playing the part of “first paying customer.”  The firm aims to engage 10-15 deals on a yearly basis and is currently open to global opportunities.

The firm is most interested in digital health, HCIT, and process transformation opportunities, and will consider medical devices (predominantly of the “wearables” and monitoring types). The firm does not consider therapeutics companies. The firm is open to various indications, but is most interested technologies targeting care administration/operations, cancer, neuroscience, and ALS.  As the firm seeks to be the first paying customer, the firm is very open to the earliest stage digital health technologies, but companies who have yet to close an angel round might be considered too early.

The firm does not have specific company or management team requirements. The firm is actively involved in the growth of their portfolio companies, and leverage their internal resources and network to support their growth and customer traction.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm with over $2 billion USD under management invests in external venture capital funds, and also has a fund to make direct investments in early stage companies. The firm focuses on investing in startups with some connection to universities who have strong ties with the firm (such as IP developed at the university or R&D being performed there) but also makes some investments into outside startups.  Initial investments are typically made at an early stage, and most are from $250,000-1 million; the firm also makes follow-on investments. The firm invests primarily in the US and also considers opportunities in Canada.

The firm invests in a wide variety of technology sectors; in the life sciences, the fund is focused on diagnostics, medical devices, and innovative areas of digital health.  The firm is opportunistic and will consider life science innovations broadly; areas of high interest include cancer care, AI, machine learning, clinical decision support systems, and imaging.  The firm will consider investing at a very early stage of development.

In addition, the firm has an additional innovation capital program for developing innovative technology in the US Midwest, including resources for incubating and accelerating new life science startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global pharmaceutical company with an established USA-based subsidiary, is interested in forming partnerships with emerging life science and digital health companies that are relevant to the company’s  pharmaceutical pipeline. These partnerships may include in-licensing, global or regional rights, and potentially also equity investments in venture financing rounds. The firm will consider partnerships with emerging companies based anywhere in the world.

The firm is interested in therapeutic assets, with a focus on the respiratory space, and also rare diseases, and cardiovascular care in a hospital setting. In North America, the firm focuses on drugs at Phase II through commercial stages; however the firm will consider opportunities at any stage from academic work onwards.  The firm is also interested in digital health solutions related to its therapeutic business, such as digital products that help with patient adherence or compliance, or which use data in ways that can help the firm understand or identify patient populations in its core areas (particularly rare diseases).

The firm does not have specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.